Bacterial Infections and Mycoses Clinical Trial
Official title:
Infant Antibiotic Resistance and Implications for Therapeutic Decision-making
Escalating resistance to antibiotics among disease-causing community bacteria increasingly
threatens our ability to treat patients' infections. At the level of the physician-patient
encounter, incentives at the patient level often take priority to society; this is often the
case with antibiotic prescribing. Each patient level antibiotic treatment decision is based
on how we value potential outcomes, including short-term benefits and risks and longer-term
risks, including those related to future bacterial resistance to antibiotics. Unfortunately,
antibiotics are often prescribed for illnesses unlikely to have a bacterial etiology; even a
very small likelihood of benefit seems to outweigh an increased risk of future antibiotic
resistance. While short-term effects of antibiotics on colonization with resistant bacteria
have been demonstrated, the overall implications of each treatment for future individual,
family and societal-level resistance remain difficult to quantify, and are often steeply
discounted or ignored during decision-making. Knowledge regarding the longer-term effects of
personal and household antibiotic use could better quantify these future resistance-related
risks, and help guide antibiotic decision-making for physicians and patients.
Infants are born with sterile nasopharyngeal and gastrointestinal tracts and yet, during the
1st year of life, become important reservoirs of resistant organisms; this creates an
opportunity to study colonization and resistance starting from a microbiological tabula
rasa. In this proposal, we will use an observational cohort to following newborns'
antibiotic exposure and longitudinal colonization with specific bacterial pathogens and
related antibiotic resistance in the 1st year of life. Our hypothesis is that during the 1st
year of life, infants with personal and household antibiotic exposure will have greater
colonization with resistan organisms than infants without antibiotic exposure. This project
will help us understand the development of bacteria that are resistant to antibiotics within
the community, and help to inform judicious decision-making regarding antibiotic
prescribing.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01968395 -
Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure
|
Phase 4 | |
Terminated |
NCT00511186 -
A Study in Sepsis Patients With Renal Failure
|
Phase 2 | |
Completed |
NCT00509938 -
Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients
|
Phase 1/Phase 2 | |
Completed |
NCT00229060 -
Doripenem in the Treatment of Complicated Intra-Abdominal Infections
|
Phase 3 | |
Completed |
NCT00210938 -
Doripenem in the Treatment of Complicated Intra-Abdominal Infections
|
Phase 3 | |
Completed |
NCT05353634 -
Metagenomic Sequencing in Clinical Infectious Diseases
|
||
Completed |
NCT02079298 -
Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants
|
Phase 4 | |
Completed |
NCT02155114 -
Iron Homoeostasis in Inflammation
|
N/A |